hg146
Small moleculeexperimental
Clinical trial activity
3 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Nov 12, 2018 (NCT03710915)
Timeline
Indications
Mechanism of action
- Histone deacetylase 2INHIBITOR
HDAC2 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06781567 | Phase 2 | Dec 13, 2024 | HitGen Inc., Shanghai Oriental Hospital |
| NCT04977167 | Phase 1 | Sep 30, 2021 | HitGen Inc. |
| NCT03710915 | Phase 1 | Nov 12, 2018 | HitGen Inc., Sichuan University |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| HitGen Inc. | For profit | 3 | 3 | 2 | 2018 |
| Shanghai Oriental Hospital | Academic/Hospital | 1 | 0 | 1 | 2024 |
| Sichuan University | Academic/Hospital | 1 | 0 | 1 | 2018 |
3 organizations
Page 1 / 1